| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| Adenosine deaminase did not increase the response of the cells to these agonists until day 30 , suggesting that the adenosine A 1 receptor inhibiting secretion does not become functional until that age . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| The effect of adenosine deaminase on terbutaline stimulated secretion was antagonized by selective adenosine A 1 receptor agonists , N 6 cyclopentyladenosine ( CPA ) and 1 deaza 2 chloro N 6 cyclopentyladenosine ( DCCA ) . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| The effects of AMPA , kainate and NMDA were attenuated or abolished by the adenosine A 1 receptor antagonist , 8 cyclopentyl 1 , 3 dipropylxanthine ( DPCPX ) as well as by adenosine A 1 receptor antagonist , 8 cyclopentyl 1 , 3 dipropylxanthine ( DPCPX ) as well as by adenosine deaminase but not by the alpha 2 adrenoceptor antagonist yohimbine , the gamma aminobutyric acid ( GABA ) receptor antagonists , bicuculline and 2 hydroxysaclofen and the NO synthase inhibitor NG nitro L arginine methyl ester ( L NAME ) . 4 . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| The methotrexate mediated reduction in leukocyte accumulation was partially reversed by injection of adenosine deaminase ( ADA ) into the air pouch , completely reversed by a specific adenosine A 2 receptor antagonist , 3 , 7 dimethyl 1 propargylxanthine ( DMPX ) , but not affected by an adenosine A 1 receptor antagonist , 8 cyclopentyl dipropylxanthine . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| In other experiments , either adenosine deaminase ( ADA ) , an adenosine A 1 receptor antagonist , or an A 2 receptor antagonist was added to a superfusate containing PAF and either MTX or adenosine . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| RESULTS : Removal of adenosine from the culture medium with adenosine deaminase resulted in an enhanced ability of the adenosine A 1 receptor agonist R N 6 ( 2 phenylisopropyl ) adenosine to exert a direct , negative inotropic effect and to inhibit isoprenaline stimulated adenylyl cyclase activity . ^^^ Binding of the antagonist radioligand [ 3H ] 8 cyclopentyl 1 , 3 dipropylxanthine in membranes from myocytes pre exposed to adenosine deaminase showed a 70 % increase in the adenosine A 1 receptor density and a 54 % increase in the proportion of the high affinity adenosine A 1 receptor : control 33 ( 5 ) % , n = 5 , versus sensitised 49 ( 3 ) % , n = 5 , p < 0 . 01 . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| The presence of adenosine deaminase in the culture increased adenosine A 1 receptor number during the period studied and induced recovery of the inhibitory effect of CPA , lost after 7 DIV . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| However , in the presence of adenosine deaminase or the selective adenosine A 1 receptor antagonist , 1 , 3 dipropyl 8 cyclopentyl xanthine ( DPCPX ) , LTD was induced by each of the first and second of two periods of LFS . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| Its inotropic action was almost completely abolished by pretreatment of atria with adenosine deaminase and correlated well with its binding ability to the cardiac adenosine A 1 receptor . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| The inhibitory effect of ATP and gamma phosphorus substituted ATP analogs ( 30 microM ) was not modified by the P 2 receptor antagonist suramin ( 100 microM ) , was inhibited by 42 49 % by the ecto 5 ' nucleotidase inhibitor and alpha , beta methylene ADP ( 100 microM ) , was inhibited by 74 85 % by 2 U / ml adenosine deaminase ( which converts adenosine into its inactive metabolite inosine ) , and was nearly prevented by the adenosine A 1 receptor antagonist 1 , 3 dipropyl 8 cyclopentylxanthine ( 10 nM ) . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| We have shown in a previous study that adenosine 5 ' triphosphate ( ATP ) depressed epileptiform activity and that this effect was blocked by the adenosine A 1 receptor antagonist cyclopentyltheophylline but was not affected by adenosine deaminase . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| The release of [ 3H ] ACh evoked by 50 mM KCl was mostly Ca2+ dependent , and it was increased in the presence of adenosine deaminase and in the presence of 1 , 3 dipropyl 8 cyclopentylxanthine ( DPCPX ) , an adenosine A 1 receptor antagonist . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| Using these cultures we observed that both [ 3H ] ACh release , which was largely Ca2+ dependent , and 45Ca2+ influx , evoked by depolarization with 50 mM KCl , were increased when adenosine A 1 receptor activation was prevented by removal of endogenous adenosine with adenosine deaminase , or by application of the A 1 receptor antagonist DPCPX . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| In the present study , we observed that degradation of this adenosine by adenosine deaminase attenuated markedly the insulin induced accumulation of phosphatidylinositol 3 , 4 , 5 trisphosphate ( PtdIns ( 3 , 4 , 5 ) P 3 ) , a product of PI 3 kinase . p Aminophenylacetyl xanthine amine congener ( PAPA XAC ) , an inhibitor of the adenosine A 1 receptor , also inhibited the insulin induced PtdIns ( 3 , 4 , 5 ) P 3 accumulation . ^^^ When extracellular adenosine was inactivated by adenosine deaminase , phenylisopropyladenosine , an adenosine A 1 receptor agonist , potentiated the insulin induced accumulation of PtdIns ( 3 , 4 , 5 ) P 3 . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| The KCl induced release of [ 3H ] ACh , but not the release of [ 14C ] GABA , was potentiated when adenosine A 1 receptor activation was prevented by perfusing the cells with adenosine deaminase ( ADA ) or with 1 , 3 dipropyl 8 cycloentylxanthine ( DPCPX ) . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| The post ATP facilitation could be prevented by the adenosine A 1 receptor antagonists 8 phenyltheophylline or 1 , 3 dipropyl 8 cyclopentyltheophylline ( 50 nM ) , or superfusion of adenosine deaminase . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| AICA riboside also depressed excitatory synaptic transmission in area CA 1 of the rat hippocampus , which was prevented by an adenosine A 1 receptor antagonist and reversed by application of adenosine deaminase . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| AIM : To study the modulating effect of adenosine deaminase ( ADA ) on the adenosine A 1 receptor ( A1R ) in HEK 293 cells stably expressing the human A1R . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| The inhibition of the EPSP induced by emodin was blocked by either 8 CPT , an adenosine A 1 receptor antagonist , or by adenosine deaminase . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| This ADA 7 ( 5 U / 30 microgram ) effect could be mimicked by the selective adenosine A 1 receptor antagonist 1 , 3 dipropyl 8 cyclopentylxanthine ( DPCPX , 10 ( 6 ) mol / l ) . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| ADA ( 5 U / ml ) stimulated the release of both hormones ( P < 0 . 01 ) as also did the selective adenosine A 1 receptor antagonist , 1 , 3 dipropyl 8 cyclopentylxanthine ( DPCPX , 0 . 1 & 1 nM , P < 0 . 01 ) ; the responses to ADA were inhibited by an A 1 receptor agonist , N 6 cyclohexyladenosine ( 0 . 1 10 nM , P < 0 . 01 ) . ^^^ |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00813 and P30542 |
Pubmed |
SVM Score :0.0 |
| NA |
|